Zantac Heartburn Medication

In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)

Print Friendly, PDF & Email


Leave a Reply

Back to Top ↑
  • Search Class-Action Tracker

  • Recent Class Actions

  • The Class-Action Tracker is intended to notify consumers about false advertising class-action lawsuits filed around the country, but does not necessarily reflect’s opinion with respect to the lawsuits or disposition of the cases

  • Sign Up for E-mail Updates